Yes but in regards to effiacy they can still look at how the placebo cohort do once they move onto the drug plus how the dosed group continue to do with cross comparisons against known average placebo scores generalized from all AD trials. Clearly not as good a compaison as a phase 3 but when they've already shown efficacy from their 2b/3 they don't need another and clearly the EMA from what they saw agreed. If Missling/Dr Kun Jin/Dr Sabbagh etc thought they needed another P3 they would have started it over a year ago. Should only take 3 months or so to release OLE results so I would guess some point in Sept (they said H2 rather than Q4 as they did for EMA submission). I would guess October for EMA submission as the rappatuer appointment timing guided things to it being around Sept so on the balance of probability it would likely be earlier in Q4 than later.
Market Data 
Markets 
